Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Qu...
28 April 2016 - 6:05AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that it plans to report its financial results for its
fiscal second quarter ended March 31, 2016 after the U.S. markets
close on May 9, 2016. Enanta management will host a conference call
at 4:30 p.m. ET to discuss these results and provide an update on
Enanta’s research and development pipeline.
Conference Call and Webcast InformationTo participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 7:30
p.m. Eastern time on May 9, 2016, through 11:59 p.m. Eastern time
on May 13, 2016 by dialing (855) 859-2056 from the U.S. or (404)
537-3406 for international callers. The passcode for both the live
call and the replay is 99296308. A live audio webcast of the call
and replay can be accessed by visiting the “Calendar of Events”
section on the “Investors” page of Enanta’s website at
www.enanta.com.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta’s research and development is currently focused on four
disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV),
Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial
Virus (RSV).
Enanta has discovered novel protease inhibitors and NS5A
inhibitors that are members of the direct-acting-antiviral (DAA)
inhibitor classes designed for use against the hepatitis C virus
(HCV). Enanta’s protease inhibitors, developed through its
collaboration with AbbVie, include paritaprevir, which is contained
in AbbVie’s marketed DAA regimens for HCV, and ABT-493, Enanta’s
second protease inhibitor, which AbbVie is developing in phase 3
studies in combination with ABT-530, AbbVie’s NS5A inhibitor.
Enanta has also discovered a cyclophilin inhibitor, EDP-494, a
novel host-targeting mechanism for HCV, which is now in phase 1
clinical development, and EDP-305, an FXR agonist, which Enanta
plans to advance into clinical development for NASH later in 2016.
Please visit www.enanta.com for more information on our programs
and pipeline.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160427006332/en/
Investor Contact:Enanta Pharmaceuticals, Inc.Carol
Miceli, 617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024